BioKangtai(SZ:300601) Xin Lang Zheng Quan·2026-01-28 01:25Group 1 - The core viewpoint of the news is that 康泰生物 (Kangtai Biological) experienced a decline in stock price and trading volume, with significant changes in financing and shareholder structure [1][2]. Group 2 - On January 27, 康泰生物's stock fell by 3.15%, with a trading volume of 690 million yuan. The financing buy-in amount for the day was 81.14 million yuan, while the financing repayment was 64.88 million yuan, resulting in a net financing buy of 16.26 million yuan. The total financing and securities balance reached 757 million yuan [1]. - As of January 27, the financing balance of 康泰生物 was 750 million yuan, accounting for 4.04% of the circulating market value, which is below the 10% percentile level over the past year, indicating a low position [1]. - The short-selling data on January 27 showed that 康泰生物 had a short-selling repayment of 20,700 shares, with no shares sold short, resulting in a short-selling balance of 688.65 million yuan, which is above the 70% percentile level over the past year, indicating a high position [1]. - As of September 30, 康泰生物 had 63,400 shareholders, an increase of 3.15% from the previous period, with an average of 14,196 circulating shares per person, a decrease of 2.99% [2]. - For the period from January to September 2025, 康泰生物 reported revenue of 2.063 billion yuan, a year-on-year increase of 2.24%, while the net profit attributable to shareholders decreased by 86.00% to 49.16 million yuan [2]. - Since its A-share listing, 康泰生物 has distributed a total of 1.765 billion yuan in dividends, with 525 million yuan distributed over the past three years [2]. - Among the top ten circulating shareholders as of September 30, 易方达创业板ETF (E Fund ChiNext ETF) held 13.2016 million shares, a decrease of 2.2175 million shares from the previous period, while 香港中央结算有限公司 (Hong Kong Central Clearing Limited) increased its holdings by 3.2916 million shares to 7.9866 million shares [2].